Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
xconomy.com » Xconomy Life Sciences Feed - Nov 15, 2008
Biotech, Roundup, Dendreon Luke Timmerman wrote: It was one of those cold, rainy November weeks in Seattle, and the headlines were pretty grim in local biotech. —Targeted Genetics (NASDAQ: TGEN) will never be the …
Also tagged: politics, cancer, microsoft, seattle, barack obama, roundup, biotech, jesse jackson, path, life sciences, fred hutchinson cancer research center, dendreon, targeted genetics, immune design, national blog main, seattle blog main, steve reed, arch venture partners, bob nelsen, id biomedical, chris elias, todd patrick, denise galloway, h stewart parker, washington biotechnology and 38 biomedical association, seattlepi
xconomy.com » Xconomy - Nov 14, 2008
Biotech, Roundup, Dendreon Luke Timmerman wrote: It was one of those cold, rainy November weeks in Seattle, and the headlines were pretty grim in local biotech. —Targeted Genetics (NASDAQ: TGEN) will never be the …
Also tagged: politics, cancer, microsoft, seattle, barack obama, roundup, biotech, jesse jackson, path, life sciences, fred hutchinson cancer research center, dendreon, targeted genetics, immune design, national blog main, seattle blog main, steve reed, arch venture partners, bob nelsen, id biomedical, chris elias, todd patrick, denise galloway, h stewart parker, washington biotechnology and 38 biomedical association
 |
Beyond Provenge: Dendreon Expands Cancer Drug Pipelinexconomy.com » Xconomy - Nov 11, 2008 Biotech, cancer, Provenge Luke Timmerman wrote: Provenge, Provenge, Provenge. The drug for prostate cancer, which is attempting to be the first approved treatment of its kind in the U.S. to actively stimulate the … Also tagged: cancer, seattle, biotech, genentech, life sciences, dendreon, neuvenge, mitchell gold, national blog main, seattle blog main, david urdal, trp p8, d 3263, lapuleucel t, sipuleucel t |
|
Beyond Provenge: Dendreon Expands Cancer Drug Pipelinexconomy.com » Xconomy Life Sciences Feed - Nov 10, 2008 Biotech, cancer, Provenge Luke Timmerman wrote: Provenge, Provenge, Provenge. The drug for prostate cancer, which is attempting to be the first approved treatment of its kind in the U.S. to actively stimulate the … Also tagged: cancer, seattle, biotech, genentech, life sciences, dendreon, neuvenge, mitchell gold, national blog main, seattle blog main, david urdal, trp p8, d 3263, lapuleucel t, sipuleucel t |
xconomy.com » Xconomy - Nov 8, 2008
Biotech, Provenge, Prostate Cancer Luke Timmerman wrote: Dendreon said today in its quarterly report that it finished the month of September with $106 million in cash and investments in the bank. The Seattle biotech …
Also tagged: seattle, biotech, prostate cancer, life sciences, dendreon, seattle briefs
xconomy.com » Xconomy Life Sciences Feed - Nov 7, 2008
Biotech, Provenge, Prostate Cancer Luke Timmerman wrote: Dendreon said today in its quarterly report that it finished the month of September with $106 million in cash and investments in the bank. The Seattle biotech …
Also tagged: seattle, biotech, prostate cancer, life sciences, dendreon, seattle briefs
xconomy.com » Xconomy - Oct 18, 2008
Biotech, Roundup, cancer Luke Timmerman wrote: It was a volatile week in the stock market, and as usual, in Seattle biotechnology. We got insights into an expansion of a biotech drug factory, the advance of a …
Also tagged: cancer, seattle, roundup, biotech, multiple sclerosis, eli lilly, cell therapeutics, life sciences, dendreon, zevalin, allozyne, sonosite, national blog main, seattle blog main, leroy hood, arch venture partners, robert nelsen, cmc icos, bernard pitz, acclerator
xconomy.com » Xconomy Life Sciences Feed - Oct 17, 2008
Biotech, Roundup, cancer Luke Timmerman wrote: It was a volatile week in the stock market, and as usual, in Seattle biotechnology. We got insights into an expansion of a biotech drug factory, the advance of a …
Also tagged: cancer, seattle, roundup, biotech, multiple sclerosis, eli lilly, cell therapeutics, life sciences, dendreon, zevalin, allozyne, sonosite, national blog main, seattle blog main, leroy hood, arch venture partners, robert nelsen, cmc icos, bernard pitz, acclerator
xconomy.com » Xconomy - Oct 15, 2008
Roundup, deals, acquisitions Gregory T. Huang wrote: Heading deep into the battles of October (hang in there, Red Sox), dealflow has been fairly strong. The Northwest saw plenty of action in mobile, biotech, health …
Also tagged: microsoft, software, mobile, it, seattle, wireless, roundup, biotech, flomerics, vc, venture capital, deals, investment, funding, bitwine, health care, scripps, investors, acquisitions, mergers, m and 38 a, action engine, dendreon, mentor graphics, azimuth, affymetrix, navigenics, chris devore, national blog main, seattle blog main, andy sack, founder s co op, monster venture partners, mobui
xconomy.com » Xconomy Venture Capital Feed - Oct 14, 2008
Roundup, deals, acquisitions Gregory T. Huang wrote: Heading deep into the battles of October (hang in there, Red Sox), dealflow has been fairly strong. The Northwest saw plenty of action in mobile, biotech, health …
Also tagged: microsoft, software, mobile, it, seattle, wireless, roundup, biotech, flomerics, vc, venture capital, deals, investment, funding, bitwine, health care, scripps, investors, acquisitions, mergers, m and 38 a, action engine, dendreon, mentor graphics, azimuth, affymetrix, navigenics, chris devore, national blog main, seattle blog main, andy sack, founder s co op, monster venture partners, mobui